ATE334695T1 - Verwendung von antizytokin-enthaltenden pharmazeutische zusammensetzungen zur therapie von multipler sklerose - Google Patents

Verwendung von antizytokin-enthaltenden pharmazeutische zusammensetzungen zur therapie von multipler sklerose

Info

Publication number
ATE334695T1
ATE334695T1 AT98104718T AT98104718T ATE334695T1 AT E334695 T1 ATE334695 T1 AT E334695T1 AT 98104718 T AT98104718 T AT 98104718T AT 98104718 T AT98104718 T AT 98104718T AT E334695 T1 ATE334695 T1 AT E334695T1
Authority
AT
Austria
Prior art keywords
anticytokine
therapy
pharmaceutical compositions
compositions containing
multiple sclerosis
Prior art date
Application number
AT98104718T
Other languages
English (en)
Inventor
David Wallach
Dan Aderka
Hartmut Engelmann
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE334695(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE334695T1 publication Critical patent/ATE334695T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98104718T 1991-05-07 1992-05-07 Verwendung von antizytokin-enthaltenden pharmazeutische zusammensetzungen zur therapie von multipler sklerose ATE334695T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL98078A IL98078A0 (en) 1991-05-07 1991-05-07 Pharmaceutical compositions comprising an anticytokyne

Publications (1)

Publication Number Publication Date
ATE334695T1 true ATE334695T1 (de) 2006-08-15

Family

ID=11062415

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98104718T ATE334695T1 (de) 1991-05-07 1992-05-07 Verwendung von antizytokin-enthaltenden pharmazeutische zusammensetzungen zur therapie von multipler sklerose
AT92107685T ATE184488T1 (de) 1991-05-07 1992-05-07 Pharmazeutische zusammensetzungen, die ein anticytokin enthalten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92107685T ATE184488T1 (de) 1991-05-07 1992-05-07 Pharmazeutische zusammensetzungen, die ein anticytokin enthalten

Country Status (12)

Country Link
EP (2) EP0512528B1 (de)
JP (1) JP3320774B2 (de)
AT (2) ATE334695T1 (de)
AU (1) AU1609492A (de)
CA (1) CA2068027C (de)
DE (2) DE69229975T2 (de)
DK (2) DK0880970T3 (de)
ES (2) ES2270479T3 (de)
GR (1) GR3031805T3 (de)
IL (1) IL98078A0 (de)
PT (1) PT880970E (de)
ZA (1) ZA923310B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
EP0486526B2 (de) 1989-08-07 2001-03-07 Peptech Limited Bindeligande für tumornekrosisfaktor
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
PT710121E (pt) * 1993-07-30 2001-04-30 Kennedy Inst Of Rheumatology T Metodo para o tratamento da esclerose multipla
JPH09508140A (ja) * 1994-07-22 1997-08-19 エフ・ホフマン−ラ ロシュ アーゲー キメラｔｎｆ結合タンパク質を含有する医薬組成物
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
ES2171547T3 (es) * 1995-07-14 2002-09-16 Applied Research Systems Receptor de tnf y hormona esteroidica dhea en terapia combinada.
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
IL127851A0 (en) * 1998-12-30 1999-10-28 Applied Research Systems Inhibition of TNF activity
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
SI1471974T1 (sl) * 2002-02-06 2007-12-31 Ares Trading Sa Tumorje nekrotizirajoäśi faktor, kombiniran z interferonom, pri demielinizirajoäśih boleznih
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SI2523688T1 (en) 2010-01-15 2018-03-30 Kirin-Amgen, Inc. Formulation of antibodies and therapeutic regimes
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
AU636608B2 (en) * 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
ES2080098T3 (es) * 1989-12-13 1996-02-01 Yeda Res & Dev Expresion de la proteina de union i al factor de necrosis tumoral tbp-i recombinante.
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
GEP20002142B (en) * 1991-01-18 2000-06-25 Amgen Inc Method for Treatment and Prevention of TNF Mediated Diseases
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JPH05170661A (ja) 1993-07-09
DE69229975T2 (de) 2000-05-11
DE69233643D1 (de) 2006-09-14
IL98078A0 (en) 1992-06-21
EP0512528A2 (de) 1992-11-11
ATE184488T1 (de) 1999-10-15
GR3031805T3 (en) 2000-02-29
JP3320774B2 (ja) 2002-09-03
EP0512528B1 (de) 1999-09-15
AU1609492A (en) 1992-11-12
DK0512528T3 (da) 1999-12-20
ES2270479T3 (es) 2007-04-01
CA2068027C (en) 2003-09-23
EP0880970A1 (de) 1998-12-02
DK0880970T3 (da) 2006-11-20
CA2068027A1 (en) 1992-11-08
PT880970E (pt) 2006-12-29
ES2137935T3 (es) 2000-01-01
EP0512528A3 (en) 1993-07-21
DE69229975D1 (de) 1999-10-21
EP0880970B1 (de) 2006-08-02
ZA923310B (en) 1993-01-27
DE69233643T2 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
DE69233643D1 (de) Verwendung von Antizytokin-enthaltenden pharmazeutische Zusammensetzungen zur Therapie von multipler Sklerose
ATE535255T1 (de) Anti-tnf antikörper und methotrexat zur gleichzeitigen behandlung von autoimmunkrankheiten
EP0787802A3 (de)
NL990033I1 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met dergelijk DNA.
KR950700937A (ko) 종양 괴사 인자 수용체로 이루어진 융합 단백질(Fusion Proteins Comprising Tumor Necrosis Factor Receptor
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
FI900808A0 (fi) Humant mannos bindande protein.
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
EP0553294A4 (en) Methods and compositions for the treatment of cell proliferation disorders
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE69334087D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
SG128403A1 (en) Tnf-receptors, tnf binding proteins and dnas coding for them
ZA9010036B (en) Expression of the recombinant tumor necrosis factor binding protein i(tbp-i)
ATE46260T1 (de) Rueckenstuetze zur physikalischen therapie von erkrankungen der wirbelsaeule.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0880970

Country of ref document: EP